Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Research & Development (2016 - 2025)

Historic Research & Development for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $3.4 million.

  • Zevra Therapeutics' Research & Development fell 6864.32% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year decrease of 5909.35%. This contributed to the annual value of $42.1 million for FY2024, which is 575.04% up from last year.
  • Latest data reveals that Zevra Therapeutics reported Research & Development of $3.4 million as of Q3 2025, which was down 6864.32% from $3.4 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Research & Development high stood at $12.3 million for Q3 2023, and its period low was $2.2 million during Q3 2021.
  • In the last 5 years, Zevra Therapeutics' Research & Development had a median value of $5.4 million in 2022 and averaged $6.4 million.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 18082.41% in 2023, then tumbled by 7346.26% in 2025.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Research & Development stood at $2.8 million in 2021, then soared by 132.86% to $6.5 million in 2022, then skyrocketed by 74.61% to $11.4 million in 2023, then fell by 26.87% to $8.4 million in 2024, then crashed by 58.91% to $3.4 million in 2025.
  • Its Research & Development stands at $3.4 million for Q3 2025, versus $3.4 million for Q2 2025 and $3.3 million for Q1 2025.